Characterization of Perinatal Stem Cell Spheroids for the Development of Cell Therapy Strategy.
Francesca ParisPasquale MarrazzoValeria PizzutiCosetta MarchionniMaura RossiMartina MichelottiBiljana PetrovicElisabetta CianiGiuliana SimonazziAndrea PessionLaura BonsiFrancesco AlvianoPublished in: Bioengineering (Basel, Switzerland) (2023)
Type 1 diabetes mellitus (T1DM) is a complex metabolic disease characterized by a massive loss of insulin-producing cells due to an autoimmune reaction. Currently, daily subcutaneous administration of exogenous insulin is the only effective treatment. Therefore, in recent years considerable interest has been given to stem cell therapy and in particular to the use of three-dimensional (3D) cell cultures to better reproduce in vivo conditions. The goal of this study is to provide a reliable cellular model that could be investigated for regenerative medicine applications for the replacement of insulin-producing cells in T1DM. To pursue this aim we create a co-culture spheroid of amniotic epithelial cells (AECs) and Wharton's jelly mesenchymal stromal cells (WJ-MSCs) in a one-to-one ratio. The resulting co-culture spheroids were analyzed for viability, extracellular matrix production, and hypoxic state in both early- and long-term cultures. Our results suggest that co-culture spheroids are stable in long-term culture and are still viable with a consistent extracellular matrix production evaluated with immunofluorescence staining. These findings suggest that this co-culture may potentially be differentiated into endo-pancreatic cells for regenerative medicine applications in T1DM.
Keyphrases
- cell therapy
- extracellular matrix
- stem cells
- induced apoptosis
- glycemic control
- type diabetes
- cell cycle arrest
- mesenchymal stem cells
- umbilical cord
- pregnant women
- bone marrow
- oxidative stress
- cell death
- signaling pathway
- multiple sclerosis
- cardiovascular disease
- physical activity
- insulin resistance
- skeletal muscle
- cell proliferation
- high resolution
- cardiovascular risk factors
- mass spectrometry